+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Biologics Market - Global Forecast 2026-2032- Product Image
Cancer Biologics Market - Global Forecast 2026-2032- Product Image
New

Cancer Biologics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 191 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011651
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cancer biologics market is undergoing significant transformation as new therapeutic modalities, regulatory adaptations, and evolving commercialization strategies redefine the oncology treatment landscape. Decision-makers require actionable insights to capitalize on growth, navigate complexity, and prioritize investments.

Market Snapshot: Cancer Biologics Market

The Cancer Biologics Market grew from USD 108.88 billion in 2025 to USD 116.58 billion in 2026. It is expected to continue growing at a CAGR of 6.59%, reaching USD 170.30 billion by 2032.

Scope & Segmentation

This report delivers a comprehensive analysis of the cancer biologics ecosystem by integrating key technology, modality, and commercial pathways shaping the industry.

  • Therapeutic Modalities: Cancer Vaccines, Cell Therapy, Gene Therapy, Monoclonal Antibodies (including anti-CD20, anti-HER2, immune checkpoint modulators, anti-VEGF), Recombinant Proteins
  • Cancer Types: Breast Cancer, Colorectal Cancer, Hematological Malignancies, Lung Cancer, Melanoma, Prostate Cancer
  • End User Settings: Ambulatory Surgery Centers, Homecare, Hospitals, Clinics, Oncology Centers
  • Distribution Channels: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Specialty Distributors
  • Regions Covered: Americas (North and South America), Europe, Middle East & Africa, Asia-Pacific

This multidimensional segmentation aligns technology choice and distribution dynamics with clinical and commercial goals, supporting portfolio and market-access strategies in oncology biologics.

Key Takeaways for Senior Leaders

  • Ongoing advances in immuno-oncology, cell and gene therapies, and antibody engineering are redefining cancer treatment modalities and creating opportunities for precision targeting and improved toxicity management.
  • Flexible regulatory approaches, such as adaptive trial designs and conditional approvals using surrogate endpoints or real-world data, allow for more expedited patient access but demand robust post-market evidence.
  • Payer environments are evolving, with increased focus on outcomes-based contracting and risk-sharing models to ensure cost-effectiveness for high-priced therapies.
  • Manufacturing innovations—including modular production platforms and supply chain integration—support scalable delivery, faster market entry, and response to fluctuating global demand.
  • Digital health technologies and decentralized clinical trials are expanding patient engagement, enabling inclusive recruitment and supporting real-world effectiveness assessment for cancer biologics.
  • Strategic collaborations—via partnerships, licensing, or co-development—provide access to novel platforms, shared risk, and accelerated commercialization, especially for emerging biotech entrants.

Tariff Impact on Cancer Biologics Supply Chains

Recent and potential United States tariff policies can alter oncology biologics supply chains, driving decisions around manufacturing localization, sourcing strategies, and contract negotiations. Cost pressures related to tariffs may prompt vertical integration among innovators and contract manufacturers. Supply chain leaders could adopt localization or supplier diversification to mitigate disruption risk. Procurement teams at hospitals and specialty distributors may revise purchasing or payment strategies to address incremental costs, while regulatory and compliance groups must adapt cost modeling for total landed expenses. Organizations leveraging analytics and flexible manufacturing footprints are positioned to adjust more effectively, providing strategic advantage in a complex global environment.

Methodology & Data Sources

This report is built on a rigorous mixed-methods protocol. Primary research involved interviews with experts in clinical development, regulation, supply chain operations, and commercialization. Secondary sources included scientific literature, regulatory documents, clinical trial registries, and public corporate disclosures. Analytical synthesis relied on cross-validation, triangulation of expert viewpoints, and iterative theme refinement to ensure objectivity and applicability, with careful attention to regional, segment, and operational variations.

Why This Report Matters

  • Enables senior leaders to align R&D, manufacturing, and commercial strategies with the latest regulatory and payer expectations for oncology biologics.
  • Supports risk mitigation and opportunity prioritization by integrating scientific, commercial, and supply chain insights across modalities and care settings.
  • Offers strategic guidance for navigating evolving market access dynamics, optimizing partnerships, and ensuring resilient product lifecycles.

Conclusion

The cancer biologics market stands at a pivotal moment of innovation and operational change. Leaders who integrate scientific strategy, supply chain resilience, and commercial discipline will position their organizations for long-term clinical and commercial impact in this evolving field.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Cancer Biologics Market, by Product Type
8.1. Cancer Vaccines
8.2. Cell Therapy
8.3. Gene Therapy
8.4. Monoclonal Antibodies
8.4.1. Anti-CD20
8.4.1.1. Obinutuzumab
8.4.1.2. Rituximab
8.4.2. Anti-HER2
8.4.2.1. Pertuzumab
8.4.2.2. Trastuzumab
8.4.3. Anti-PD-1/PD-L1
8.4.3.1. Atezolizumab
8.4.3.2. Nivolumab
8.4.3.3. Pembrolizumab
8.4.4. Anti-VEGF
8.5. Recombinant Proteins
9. Cancer Biologics Market, by Cancer Type
9.1. Breast Cancer
9.2. Colorectal Cancer
9.3. Hematological Malignancies
9.4. Lung Cancer
9.5. Melanoma
9.6. Prostate Cancer
10. Cancer Biologics Market, by End User
10.1. Ambulatory Surgery Centers
10.2. Homecare Settings
10.3. Hospitals & Clinics
10.4. Oncology Centers
11. Cancer Biologics Market, by Distribution Channel
11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.3. Retail Pharmacies
12. Cancer Biologics Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Cancer Biologics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Cancer Biologics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Cancer Biologics Market
16. China Cancer Biologics Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AbbVie Inc.
17.6. ADC Therapeutics SA
17.7. Agenus Inc.
17.8. Amgen Inc.
17.9. AstraZeneca PLC
17.10. Autolus Therapeutics plc
17.11. BeiGene, Ltd.
17.12. Biocon Limited
17.13. BioNTech SE
17.14. Bristol-Myers Squibb Company
17.15. F. Hoffmann-La Roche Ltd.
17.16. GlaxoSmithKline plc
17.17. Johnson & Johnson
17.18. Merck & Co., Inc.
17.19. Modex Therapeutics AG
17.20. Novartis AG
17.21. Pfizer Inc.
17.22. Regeneron Pharmaceuticals, Inc.
17.23. Sanofi S.A.
17.24. Seagen Inc.
List of Figures
FIGURE 1. GLOBAL CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CANCER BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CANCER BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY OBINUTUZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY OBINUTUZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY OBINUTUZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RITUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PERTUZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PERTUZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PERTUZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY TRASTUZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY TRASTUZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. EUROPE CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. EUROPE CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 136. EUROPE CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 137. EUROPE CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 138. EUROPE CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 139. EUROPE CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 140. EUROPE CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 141. EUROPE CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. EUROPE CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 147. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 148. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. AFRICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 154. AFRICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 155. AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 156. AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 157. AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 158. AFRICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 159. AFRICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. AFRICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 170. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 171. ASEAN CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. ASEAN CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 173. ASEAN CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 174. ASEAN CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 175. ASEAN CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 176. ASEAN CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 177. ASEAN CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 178. ASEAN CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. ASEAN CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. GCC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. GCC CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 182. GCC CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 183. GCC CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 184. GCC CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 185. GCC CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 186. GCC CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 187. GCC CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 188. GCC CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. BRICS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. BRICS CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 200. BRICS CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 201. BRICS CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 202. BRICS CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 203. BRICS CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 204. BRICS CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 205. BRICS CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 206. BRICS CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 207. G7 CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. G7 CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 209. G7 CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 210. G7 CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 211. G7 CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 212. G7 CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 213. G7 CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 214. G7 CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 215. G7 CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 216. NATO CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. NATO CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 218. NATO CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 219. NATO CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 220. NATO CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 221. NATO CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 222. NATO CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 223. NATO CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 224. NATO CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 225. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 230. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 233. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 234. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 235. CHINA CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 236. CHINA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 237. CHINA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 238. CHINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
TABLE 239. CHINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
TABLE 240. CHINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
TABLE 241. CHINA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 242. CHINA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 243. CHINA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Cancer Biologics market report include:
  • AbbVie Inc.
  • ADC Therapeutics SA
  • Agenus Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Autolus Therapeutics plc
  • BeiGene, Ltd.
  • Biocon Limited
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Modex Therapeutics AG
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Seagen Inc.

Table Information

Report AttributeDetails
No. of Pages191
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 116.58 Billion
Forecasted Market Value ( USD ) by 2032 $ 170.3 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Biologics Targeting CCR4 Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Biologics Targeting CCR4 Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Biologics Market Size, Share, Trends and Forecast by Source, Product, Disease, Manufacturing, and Region, 2025-2033 - Product Image

Biologics Market Size, Share, Trends and Forecast by Source, Product, Disease, Manufacturing, and Region, 2025-2033

  • Report
  • 149 Pages
  • Global
From
Cancer Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Cancer Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 181 Pages
  • Global
From
Inhalable Biologics Market Size, Share & Trends Analysis Report by Biologics (Peptides & Proteins, Monoclonal Antibodies, RNAi-Based Therapeutics), Application (Diabetes, Cancer), Dosage Form, Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Inhalable Biologics Market Size, Share & Trends Analysis Report by Biologics (Peptides & Proteins, Monoclonal Antibodies, RNAi-Based Therapeutics), Application (Diabetes, Cancer), Dosage Form, Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Cancer biologics Market Report 2025 - Product Image

Cancer biologics Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Cancer Biologics Market

The Cancer Biologics market is a subset of the larger Biotechnology industry. It focuses on the development and commercialization of biologic drugs for the treatment of cancer. These drugs are typically derived from living organisms, such as proteins, antibodies, and other molecules, and are used to target and treat cancer cells. They are often used in combination with other treatments, such as chemotherapy and radiation therapy, to improve outcomes. Cancer biologics are typically developed through a combination of laboratory research, clinical trials, and regulatory approval. Companies in this market are typically involved in the research, development, manufacturing, and marketing of these drugs. Notable companies in the Cancer Biologics market include Amgen, Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.